Abstract
In this article, the four coordinators of neglected tropical disease (NTD) drug development projects funded under the European Commission (EC) Framework Programme 7 argue that the EC should reassess their funding strategy to cover the steps necessary to translate a lead compound into a drug candidate for testing in clinical trials, and suggest ways in which this might be achieved.
| Original language | English |
|---|---|
| Pages (from-to) | 581-583 |
| Number of pages | 3 |
| Journal | Trends in Parasitology |
| Volume | 33 |
| Issue number | 8 |
| Early online date | 18 May 2017 |
| DOIs | |
| Publication status | Published - Aug 2017 |
Funding
| Funders | Funder number |
|---|---|
| Seventh Framework Programme | 603240 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being -
SDG 17 Partnerships for the Goals
Fingerprint
Dive into the research topics of 'The Future of Drug Development for Neglected Tropical Diseases: How the European Commission Can Continue to Make a Difference'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver